

RESEARCH

Open Access

Antibiotic prescription patterns in the empiric therapy of severe sepsis: combination of antimicrobials with different mechanisms of action reduces mortality

Ana Díaz-Martín^{1,2,3*}, María Luisa Martínez-González⁴, Ricard Ferrer^{5,6}, Carlos Ortiz-Leyba^{1,2,3}, Enrique Piacentini⁵, María Jesus Lopez-Pueyo⁷, Ignacio Martín-Loeches^{4,6}, Mitchell M Levy⁸, Antoni Artigas^{4,6}, José Garnacho-Montero^{1,2,3} and for the Edusepsis Study Group

Abstract

Introduction: Although early institution of adequate antimicrobial therapy is lifesaving in sepsis patients, optimal antimicrobial strategy has not been established. Moreover, the benefit of combination therapy over monotherapy remains to be determined. Our aims are to describe patterns of empiric antimicrobial therapy in severe sepsis, assessing the impact of combination therapy, including antimicrobials with different mechanisms of action, on mortality.

Methods: This is a Spanish national multicenter study, analyzing all patients admitted to ICUs who received antibiotics within the first 6 hours of diagnosis of severe sepsis or septic shock. Antibiotic-prescription patterns in community-acquired infections and nosocomial infections were analyzed separately and compared. We compared the impact on mortality of empiric antibiotic treatment, including antibiotics with different mechanisms of action, termed different-class combination therapy (DCCT), with that of monotherapy and any other combination therapy possibilities (non-DCCT).

Results: We included 1,372 patients, 1,022 (74.5%) of whom had community-acquired sepsis and 350 (25.5%) of whom had nosocomial sepsis. The most frequently prescribed antibiotic agents were β -lactams (902, 65.7%) and carbapenems (345, 25.1%). DCCT was administered to 388 patients (28.3%), whereas non-DCCT was administered to 984 (71.7%). The mortality rate was significantly lower in patients administered DCCTs than in those who were administered non-DCCTs (34% versus 40%; $P = 0.042$). The variables independently associated with mortality were age, male sex, APACHE II score, and community origin of the infection. DCCT was a protective factor against in-hospital mortality (odds ratio (OR), 0.699; 95% confidence interval (CI), 0.522 to 0.936; $P = 0.016$), as was urologic focus of infection (OR, 0.241; 95% CI, 0.102 to 0.569; $P = 0.001$).

Conclusions: β -Lactams, including carbapenems, are the most frequently prescribed antibiotics in empiric therapy in patients with severe sepsis and septic shock. Administering a combination of antimicrobials with different mechanisms of action is associated with decreased mortality.

* Correspondence: anukadiaz@gmail.com

¹Intensive Care Unit, Critical Care and Emergency Department, Virgen del Rocío University Hospital, Avda. Manuel Siurot s/n, Seville 41013, Spain
Full list of author information is available at the end of the article

Introduction

Sepsis is a prevalent disorder and one of the main causes of death among hospitalized patients. Treating sepsis is associated with high costs; however, despite advances in medical practice, the mortality rate of sepsis has not declined in recent decades [1]. In Spain, the incidence of severe sepsis is 104 cases per 100,000 adult residents per year, and related in-hospital mortality is 20.7%; the incidence of septic shock is 31 cases per 100,000 adult residents per year, and related in-hospital mortality is 45.7% [2]. Sepsis present at intensive care unit (ICU) admission and ICU-acquired sepsis clearly differ in the types of patients affected, the sources of infection, the microorganisms responsible, and the prognosis [3].

Diverse studies have confirmed that the prompt institution of antimicrobial therapy active against the causative pathogen is lifesaving in patients with severe sepsis [4,5]. The Surviving Sepsis Campaign strongly recommends initiating antibiotic therapy within the first hour of recognition of severe sepsis, after suitable samples have been obtained for cultures [6].

Nevertheless, although antibiotic therapy is the cornerstone in the treatment of sepsis, the optimal antimicrobial strategy has not been defined. Few data are available about antibiotic prescription patterns used most in severe sepsis.

Furthermore, the advantages and disadvantages of combination therapy compared with monotherapy are controversial, and studies comparing the two approaches have mainly been limited to bacteremia, pneumonia, or serious *Pseudomonas aeruginosa* infections [7-9]. Importantly, a recent retrospective study concluded that certain combinations of antimicrobials, including antimicrobials with different targets, improve survival in patients with septic shock [10].

We present a secondary analysis of the Edusepsis study, which enrolled all patients with severe sepsis and septic shock admitted to the participating ICUs during 2 months in 2005 and 4 months in 2006. Our aims are (a) to describe the patterns of empiric antimicrobial therapy, analyzing the differences between community-acquired and nosocomial infections; and (b) to compare the impact on mortality of combination therapy, including at least two antimicrobials with different mechanisms of action, with that of monotherapy and other combinations of antimicrobials.

Materials and methods

Design of the study

We conducted a secondary analysis of the Edusepsis study, a Spanish national multicenter before-and-after study involving 77 ICUs [11]. In this study, carried out between November 2005 and 2007, data were collected before and after a 2-month educational intervention

based on the Surviving Sepsis Campaign guidelines; this approach to improving treatment of severe sepsis is cost-effective [12]. Each participating centers' research and ethical-review boards approved the study, and patients remained anonymous. The need for informed consent was waived in view of the observational and anonymous nature of the study.

The study included all patients in these ICUs with severe sepsis or septic shock. The study design is described in detail elsewhere [11]. In brief, severe sepsis was defined as sepsis associated with organ dysfunction unexplained by other causes. Septic shock was defined as sepsis associated with systolic blood pressure <90 mm Hg, mean arterial pressure <65 mm Hg, or a reduction in systolic blood pressure >40 mm Hg from baseline despite adequate volume resuscitation. Patients in whom the onset of severe sepsis could not be determined were excluded from the analysis. The approach to data collection and the quality-control measures to assure data reliability also are described elsewhere [11,12].

Variables

The following variables were recorded: demographic characteristics (age and gender), types of patients (medical, trauma, emergency surgery, elective surgery), sources of infection, location at sepsis acquisition (community-acquired or nosocomial infection), and baseline lactate level and organ dysfunction at sepsis diagnosis. Severity of illness was evaluated by the Acute Physiology and Chronic Health Evaluation (APACHE) II score, considering the worst reading in the first 24 hours in the ICU [13]. All patients were followed up until death or hospital discharge. The primary outcome variable was in-hospital mortality.

Antimicrobial therapy

The antimicrobial therapy prescribed at the diagnosis of severe sepsis and the time from severe sepsis presentation to antibiotic administration were recorded. To facilitate subsequent analysis, antimicrobial agents were grouped into eight antibiotic families: β -lactams (except carbapenems), carbapenems, quinolones, macrolides, aminoglycosides, anti-gram-positive antibiotics (vancomycin, teicoplanin, and linezolid), antifungal agents, and other antimicrobial agents (including antiviral and tuberculostatic agents). Data for community-acquired and nosocomial infections also were analyzed separately. We also compared the clinical characteristics of patients that received different-class combination therapy (DCCT) with those of patients that received any other antimicrobial therapy (non-DCCT).

DCCT was defined as the concomitant use of two or more antibiotics of different mechanistic classes, as recently defined by Kumar *et al.* [10], specifically β -lactams or

carbapenems with aminoglycosides, fluoroquinolones, or macrolides/clindamycin. Monotherapy or any other combination therapy was considered non-DCCT for this analysis.

To assess the impact of DCCT on mortality, we analyzed only patients who received the first dose of antimicrobial within the first 6 hours after severe sepsis presentation.

Statistical analysis

Discrete variables were expressed as frequencies (percentage), and continuous variables, as means and standard deviations (SDs), unless stated otherwise; all statistical tests were two-sided. Differences in categoric variables were calculated by using χ^2 tests or Fisher Exact test, and differences in continuous variables were calculated by using the Mann-Whitney *U* or Kruskal-Wallis test, as appropriate.

Backward logistic regression was used to assess the factors independently associated with in-hospital mortality. To avoid spurious associations, variables entered in the regression models were those with a relation in univariate

analysis ($P \leq 0.05$) or a plausible relation with the dependent variable. SPSS for Windows 20.0 (SPSS, Chicago, IL, USA) was used for all statistical analyses.

Results and discussion

Descriptive analysis

The Edusepsis study included 2,796 patients with severe sepsis or septic shock; we analyzed the 1,372 patients that received antibiotic therapy in the first 6 hours from the diagnosis of sepsis, of whom 1,022 (74.5%) had community-acquired sepsis and 350 (25.5%) had nosocomial sepsis. Table 1 shows the study group's main demographics, APACHE II scores, levels of lactate, and diagnoses on admission.

The most frequent sources of sepsis were pneumonia ($n = 502$; 36.6%), followed by abdominal infection ($n = 390$; 28.48%), urinary tract infection ($n = 182$; 13.3%), central nervous system infection ($n = 50$; 3.6%), skin or soft-tissue infection ($n = 54$; 3.9%), and catheter-related infection ($n = 24$; 1.7%).

Table 1 Demographic and clinical characteristics of the patients

	Global <i>n</i> = 1,372	Community-acquired <i>n</i> = 1,022 (74.5%)	Nosocomial <i>n</i> = 350 (25.5%)	<i>P</i>
General data				
Sex (male)	837 (61%)	623 (61%)	214 (61%)	0.999
Age (years)	62.24 ± 16.22	62.00 ± 16.65	62.93 ± 14.87	0.354
APACHE II	21.44 ± 7.54	21.09 ± 7.49	22.45 ± 7.61	0.004
Lactate (mM)	35.56 ± 26.94	36.76 ± 27.68	32.06 ± 24.37	0.020
Diagnosis on admission				
Medical	893 (65.4%)	734 (72%)	159 (45.8%)	
Trauma	25 (1.8%)	8 (0.8%)	17 (4.9%)	<0.001
Emergency surgery	382 (28%)	256 (25.1%)	126 (36.3%)	
Elective surgery	66 (4.86%)	21 (2.1%)	45 (13%)	
Type of infection				
Pneumonia	502 (36.6%)	362 (35.4%)	140 (40%)	
Abdominal	390 (28.4%)	270 (26.4%)	120 (34.3%)	
Urologic	182 (13.3%)	163 (15.9%)	19 (5.4%)	
Meningitis	50 (3.6%)	47 (4.6%)	3 (0.9%)	<0.001
SSTI	54 (3.9%)	46 (4.5%)	8 (2.3%)	
Catheter	24 (1.7%)	6 (0.6%)	18 (5.1%)	
Others	138 (3.1%)	108 (10.6%)	30 (8.6%)	
More than one focus	32 (2.3%)	20 (2.0%)	12 (3.4%)	
Organ failure				
Hemodynamic	1,129 (82.3%)	845 (82.7%)	284 (81.1%)	0.517
Respiratory	880 (64.1%)	641 (62.7%)	239 (68.3%)	0.062
Renal	1,006 (73.3%)	754 (73.8%)	252 (72.0%)	0.529
Hepatic	238 (17.3%)	176 (17.2%)	62 (17.7%)	0.870
Hematologic	344 (25.1%)	266 (26.0%)	78 (22.3%)	0.175
Coagulation	502 (36.6%)	394 (38.6%)	108 (30.9%)	0.010
Mortality	526 (38.3%)	356 (34.8%)	170 (48.6%)	<0.001

Antimicrobial treatments prescribed

The most frequently prescribed antibiotic agents were β -lactams ($n = 902$; 65.7%), carbapenems ($n = 345$; 25.1%), and quinolones ($n = 282$; 20.6%). Table 2 presents the data for the entire group of patients who received empiric antibiotic therapy within 6 hours of admission, and for the groups of patients with community-acquired ($n = 1,022$; 74.5%) and nosocomial infections ($n = 350$; 25.5%).

The distribution of the antibiotics prescribed for community-acquired infections was similar to that for the overall group, with predominance of β -lactams ($n = 708$; 69.3%), quinolones ($n = 241$; 23.6%), and carbapenems ($n = 218$; 21.3%), whereas in the group with nosocomial infections, although β -lactams were also the most-used treatment ($n = 194$; 55.4%), carbapenems were second ($n = 127$; 36.3%), followed by aminoglycosides ($n = 69$; 19.7%) and anti-gram-positive agents ($n = 65$; 18.6%). Macrolides and quinolones were more frequently used in community-acquired sepsis than in nosocomial sepsis (see Table 2).

DCCT and non-DCCT groups

DCCTs were administered to 388 patients (28.3%), and non-DCCTs, to 984 (71.7%). Table 3 shows the demographic characteristics, diagnosis at admission, incidence of associated organ failure, and sources of infection of patients in the DCCT and non-DCCT groups. Sex distribution, age, APACHE II score, and lactate levels were very similar in the two groups.

Significant differences between the two groups were found in diagnosis at admission and source of infection. In the DCCT group, the percentage of patients with medical diagnoses was higher (79.9% versus 59.6%; $P < 0.001$) and the percentage with emergency surgical diagnoses was lower (15.2% versus 33%; $P < 0.001$). The most common source of sepsis was pneumonia in the DCCT group (59% versus 27.7%; $P < 0.001$) and abdominal infection in the non-DCCT group (14.4% versus 33.9%; $P < 0.001$).

Although the median number of organ failures was the same in both groups, significant differences were noted in the organ-failure distribution: respiratory failure was

more common in the DCCT group (74.5% versus 60.1%; $P < 0.001$) and renal failure was more common in the non-DCCT group (68% versus 75.4%; $P = 0.007$).

In the DCCT group, the most frequently used agents were β -lactams ($n = 320$; 82.5%), followed by quinolones ($n = 186$; 47.9%), aminoglycosides ($n = 158$; 40.7%), and carbapenems ($n = 76$; 19.6%) (Table 4). These agents were used in the following combinations: (a) a β -lactam plus an aminoglycoside or a quinolone or a macrolide ($n = 312$; 80.4%); the most common combination in this group was a β -lactam plus a quinolone ($n = 163$; 52.2%); (b) a carbapenem plus an aminoglycoside or a quinolone or a macrolide ($n = 68$; 17.5%); the most common combination in this group was a carbapenem plus an aminoglycoside ($n = 46$; 67.6%); and (c) a β -lactam plus a carbapenem ($n = 8$; 2.1%), usually associated with an aminoglycoside ($n = 6$; 75.0%) (data not shown in table). It is noteworthy that DCCT consisted only of a β -lactam or carbapenem plus a macrolide and/or an aminoglycoside and/or a quinolone in 311 (80%) patients; thus, other antimicrobials (antifungals, anti-gram-positive agents, and so on) were also administered in DCCT in only 75 (20%) (data not shown).

Predictors of mortality

In the univariate analysis, factors significantly associated with mortality were gender, age, APACHE II score, lactate levels, source of infection, and DCCT (Table 5). Mortality was significantly lower in the DCCT group (34.0% versus 40%; $P = 0.042$). In the multivariate analysis (Table 6), including the variables that were significantly associated with mortality in the univariate analysis, higher age (OR, 1.023; 95% CI, 1.014 to 1.032; $P < 0.001$), male sex (OR, 1.350; 95% CI, 1.041 to 1.750; $P = 0.024$), higher APACHE II score (OR, 1.099; 95% CI, 1.099 to 1.141; $P < 0.001$), and community-acquired infection (OR, 1.487; 95% CI, 1.119 to 1.974; $P = 0.006$) was associated with higher mortality, whereas urologic focus of infection (OR, 0.241; 95% CI, 0.102 to 0.569; $P = 0.001$) and DCCT were associated with lower mortality (OR, 0.699; 95% CI, 0.522 to 0.936; $P = 0.016$).

Table 2 Antibiotic distribution in the entire cohort and in patients with community-acquired and nosocomial sepsis

Antibiotics	Global $n = 1,372$	Community-acquired $n = 1,022$ (74.5%)	Nosocomial $n = 350$ (25.5%)	<i>P</i>
β -lactams	902 (65.7%)	708 (69.3%)	194 (55.4%)	<0.001
Carbapenems	345 (25.1%)	218 (21.3%)	127 (36.3%)	<0.001
Quinolones	282 (20.6%)	241 (23.6%)	41 (11.7%)	<0.001
Aminoglycosides	183 (13.3%)	114 (11.2%)	69 (19.7%)	<0.001
Macrolides	60 (4.4%)	54 (5.3%)	6 (1.7%)	0.004
Anti-gram-positive	161 (11.7%)	96 (9.4%)	65 (18.6%)	<0.001
Antifungals	38 (2.8%)	20 (2.0%)	18 (5.1%)	0.004
Others	151 (11.0%)	111 (10.9%)	40 (11.4%)	0.767

Table 3 Comparisons of patients treated with DCCT or non-DCCT

	DCCT group <i>n</i> = 388 (28.3%)	Non-DCCT group <i>n</i> = 984 (71.7%)	<i>P</i>
General data			
Sex (male)	247 (63.7%)	590 (60%)	0.219
Age (years)	60.88 ± 16.79	62.78 ± 15.96	0.057
APACHE II	21.35 ± 7.43	21.47 ± 7.58	0.790
Lactate (mM)	36.37 ± 26.99	35.22 ± 26.93	0.578
Diagnosis on admission			
Medical	310 (79.9%)	583 (59.6%)	<0.001
Trauma	3 (0.8%)	22 (2.2%)	0.074
Emergency surgery	59 (15.2%)	323 (33%)	<0.001
Elective surgery	16 (4.1%)	50 (5.1%)	0.487
Type of infection			
Abdominal	56 (14.4%)	334 (33.9%)	<0.001
Urologic	44 (11.3%)	138 (14%)	0.216
Meningitis	5 (1.3%)	45 (4.6%)	0.002
Skin and/or soft-tissue	6 (1.5%)	48 (4.9%)	0.003
Catheter	4 (1%)	20 (2%)	0.256
Others	31 (8%)	107 (10.9%)	0.134
More than one focus	13 (3.4%)	19 (1.9%)	0.162
Organ failure			
Number of organ failures	2.98 ± 1.26	2.98 ± 1.25	0.955
Hemodynamic	319 (82.2%)	810 (82.3%)	0.999
Respiratory	289 (74.5%)	591 (60.1%)	<0.001
Renal	264 (68%)	742 (75.4%)	0.007
Hepatic	61 (15.7%)	177 (18%)	0.343
Hematologic	94 (24.2%)	250 (25.4%)	0.679
Coagulation	131 (33.8%)	371 (37.7%)	0.191
Mortality	132 (34%)	394 (40%)	0.042

For the DCCT-combination treatments associated with reductions in mortality, the results of the analysis, excluding patients who died within the first 6 hours, were similar to the results including these patients; hence, no evidence of immortal bias was found in our results.

Discussion

This secondary analysis of the Edusepsis study reveals interesting data about the patterns of antibiotic prescription

in patients with severe sepsis and septic shock and about the characteristics of patients receiving combination therapy, including antimicrobials, with different mechanisms of action (DCCTs) versus those receiving either monotherapy or any other combinations of antimicrobials (non-DCCTs). Our study confirms the increased survival in patients administered DCCTs (β -lactams plus aminoglycosides, quinolones, or macrolides/clindamycin) within the first 6 hours of severe sepsis presentation. We excluded patients that

Table 4 Antibiotic prescription in patients treated with DCCT or non-DCCT

Antibiotics	Non-DCCT group <i>n</i> = 984 (71.7%)	DCCT group <i>n</i> = 388 (28.3%)	<i>P</i>
β -Lactams	582 (59.1%)	320 (82.5%)	<0.001
Carbapenems	269 (27.3%)	76 (19.6%)	0.003
Quinolones	96 (9.8%)	186 (47.9%)	<0.001
Aminoglycosides	25 (2.5%)	158 (40.7%)	<0.001
Macrolides	7 (0.7%)	53 (13.7%)	<0.001
Anti-gram-positive	120 (12.2%)	41 (10.6%)	0.456
Antifungals	21 (2.1%)	17 (4.4%)	0.028
Others	121 (12.3%)	30 (7.7%)	0.016

Table 5 Univariate analysis of factors associated with in-hospital mortality

	Global n = 1,372	Survivors n = 846 (61.7%)	Nonsurvivors n = 526 (38.3%)	P
General data				
Sex (male)	837 (61.0%)	489 (57.8%)	348 (66.2%)	0.002
Age (years)	62.2 ± 16.2	59.80 ± 16.81	66.16 ± 14.39	<0.001
APACHE II	21.4 ± 7.5	19.20 ± 6.86	25.09 ± 7.17	<0.001
Lactate (mM)	35.6 ± 26.9	31.09 ± 22.54	43.09 ± 31.69	<0.001
Type of infection				
Pneumonia	502 (36.6%)	289 (34.2%)	213 (40.5%)	
Abdominal	390 (28.4%)	228 (27%)	162 (30.8%)	
Urologic	181 (13.3%)	142 (16.8%)	40 (7.6%)	
Meningitis	50 (3.6%)	40 (4.7%)	10 (1.9%)	<0.001
Skin and soft-tissue	54 (3.9%)	37 (4.4%)	17 (3.2%)	
Catheter	24 (1.7%)	15 (1.8%)	9 (1.7%)	
Others	138 (10.1%)	78 (9.2%)	60 (11.4%)	
More than one focus	32 (2.3%)	17 (2%)	15 (2.9%)	
Community acquired	1,022 (74.5%)	666 (78.7%)	356 (67.7%)	<0.001
DCCT	388 (28.3%)	256 (30.3%)	132 (25.1%)	0.042

received antimicrobial therapy after 6 hours of severe sepsis diagnosis from this analysis, because strong evidence indicates that early administration increases survival in patients with severe sepsis or septic shock [4,5,10].

Appropriate empiric antimicrobial therapy is crucial for the survival of sepsis patients [4,5]. Formerly, multidrug-resistant pathogens were found almost exclusively in nosocomial infections. However, community-acquired infections are now often caused by antibiotic-resistant bacteria (for example, extended-spectrum β -lactamase-producing Enterobacteriaceae, multidrug-resistant *Pseudomonas aeruginosa*, or methicillin-resistant *Staphylococcus aureus*) [14,15]. This striking change in epidemiology may explain why the initial therapy frequently includes a combination of different antimicrobial agents [16].

Table 6 Multivariate analysis of risk factors for mortality

Factors	OR	CI (95%)	P
Age (years)	1.023	(1.014-1.032)	<0.001
Sex (male)	1.350	(1.041-1.750)	0.024
APACHE II	1.099	(1.099-1.141)	<0.001
Community-acquired	1.487	(1.119-1.974)	0.006
DCCT	0.699	(0.522-0.936)	0.016
Focus of infection			
Pneumonia	0.784	(0.358-1.718)	0.543
Abdominal	0.595	(0.269-1.317)	0.200
Urologic	0.241	(0.102-0.569)	0.001
Meningitis	0.357	(0.122-1.046)	0.060
Skin and soft-tissue	0.424	(0.157-1.141)	0.089
Catheter	0.441	(0.135-1.445)	0.177
Others	0.772	(0.330-1.806)	0.551
More than one focus	1		

β -Lactams, including carbapenems, are the most commonly used antibiotics in the critical care setting [17]. Likewise, this antibiotic family constitutes the mainstay of empiric treatment in patients with severe sepsis or septic shock, whether administered alone or in combination with other antimicrobials. Carbapenems are more frequently prescribed in patients with nosocomial sepsis, although it is worth mentioning that one in five patients with community-acquired sepsis is treated empirically with a carbapenem. This may reflect the increase in multidrug-resistant gram-negative pathogens in the community [14]. Carbapenems might have been analyzed in conjunction with the rest of β -lactams. However, we decided to analyze them separately from other β -lactams because of the broader-spectrum, major role in empiric antibiotic therapy and the widespread use in the ICU.

Quinolones are used mainly in community-acquired infections and in combination therapy [18]. The extended use of quinolones in combination therapy in patients with severe community-acquired pneumonia may explain the increasing rate of quinolone resistance among nosocomial gram-negative pathogens [18,19].

Numerous studies have evaluated the likely superiority of combination therapy in patients with diverse types of infections. A French multicenter study of critical patients with acute peritonitis found no difference in the rate of therapeutic failure or length of antibiotic treatment when β -lactams were administered alone or in combination with aminoglycosides, concluding that aminoglycosides should be added only when an infection by *Pseudomonas* spp or *Enterococcus* spp is suspected [20]. Two randomized clinical trials found no benefits of combination therapy over monotherapy in patients with ventilator-

associated pneumonia [21,22]. Moreover, in one trial, monotherapy was associated with lower rates of therapeutic failure, superinfection, and side effects [22].

Conversely, diverse studies have demonstrated lower mortality and length of stay in patients with pneumococcal bacteremia or with community-acquired pneumonia receiving combination therapy, including a β -lactam plus a macrolide or a quinolone, than in those receiving monotherapy [23-25]. In these studies, the benefits seem to be restricted to more-severe patients or to those in septic shock [18,23]. Conversely, a recent retrospective study concluded that, in bacteremia caused by gram-negative bacilli, combination therapy with β -lactams and fluoroquinolones was associated with a reduction in 28-day crude mortality only among less severely ill patients [7].

Two meta-analyses of studies performed in patients with gram-negative bacteremia or sepsis found no benefit of combination therapy over monotherapy, except when bacteremia was caused by multidrug-resistant bacteria or *Pseudomonas* spp [26,27]. Moreover, higher rates of side effects (mainly nephrotoxicity) were reported in the group of patients treated with β -lactam antibiotics plus aminoglycosides. More recently, a meta-analytic/meta-regression study that included 50 studies found that combination antibiotic therapy improves survival, particularly in septic shock patients, but may be harmful to less severely ill patients [28].

Nevertheless, few data are available about the impact on the outcome of combination therapy in large cohorts of patients with severe sepsis or septic shock. A recent propensity-matched analysis concluded that, in patients with septic shock, the use of combination therapy with two or more antibiotics of different mechanistic classes was associated with lower 28-day mortality, shorter ICU stay, and lower in-hospital mortality [10].

Our results confirm that combination therapy, including two or more antimicrobials with different mechanisms of action (β -lactams in combination with aminoglycosides, fluoroquinolones, or macrolides/clindamycin), administered within the first 6 hours of sepsis presentation is an independent protective factor against in-hospital mortality. Interestingly, severity of illness measured by APACHE II score, basal lactate levels, and the presence of hemodynamic failure did not differ between patients receiving DCCTs and those receiving non-DCCTs.

The choice of empiric antimicrobial therapy is based on the clinical presentation of the infection, the characteristics of the patient, the local ecology, and previous antibiotic exposure. Reducing the antibiotic pressure and side effects are the main reasons for choosing monotherapy. Conversely, the main reason for prescribing combination therapy for critically ill sepsis patient is to broaden the antimicrobial spectrum in an attempt to ensure the coverage of all likely pathogens. Our results permit us to speculate that

the synergistic mechanisms of different antimicrobial combinations, or the immunomodulatory effects described with macrolides and quinolones, may be of clinical transcendence in patients with severe sepsis or septic shock [29-31].

Our study has several limitations. First, a major limitation in our study is the lack of microbiology data due to the initial study design. Accordingly, no data are available on antibiotic susceptibility, appropriateness of antimicrobial therapy, or the presence of bacteremia. Appropriate antimicrobial therapy based on culture results was an important determinant of survival in a large cohort of patients with severe sepsis [32].

Second, because of the absence of microbiology data, we cannot explore whether the positive impact on mortality observed with DCCTs is related to a synergistic effect of two mechanistically distinct antibiotics or a broader range of coverage with two or more agents.

Third, we did not evaluate source control and other important measures included in the Surviving Sepsis Campaign care bundles.

Fourth, this is a secondary analysis of an observational study. Nevertheless, properly designed observational studies with the appropriate analytic approach can provide valuable information on treatment effectiveness [4].

However, our study has also important strengths. We prospectively enrolled a large cohort of ICU patients with severe sepsis and septic shock in a short time and monitored them until death or hospital discharge, resulting in a homogeneous database with high quality-control measures that assure data validity [4]. Finally, our conclusions are strengthened by absence of immortal bias.

Conclusions

β -Lactams, including carbapenems, are the mainstay of empiric therapy in patients with severe sepsis and septic shock. Carbapenems are more frequently prescribed in patients with nosocomial sepsis, although up to one in five patients with community-acquired sepsis is treated empirically with a carbapenem. Our study supports the hypothesis that early administration of antimicrobials with different mechanistic targets is associated with decreased in-hospital mortality. Our findings extend those of the propensity-matched analysis in patients with septic shock published by Kumar *et al.* [10] because we also included patients with severe sepsis, underlining the urgent need for well-designed randomized controlled trials to evaluate the clinical benefit of DCCTs in critically ill sepsis patients.

Key messages

- β -Lactams, including carbapenems, are the antibiotics most usually used in the critical care setting.
- Although carbapenems are more frequently prescribed in patients with nosocomial sepsis, one in five

patients with community-acquired sepsis is treated empirically with a carbapenem.

- Urologic focus of infection is associated with the lowest mortality rate in patients with severe sepsis or septic shock.
- In our series, the mortality rate was significantly lower in patients receiving DCCTs than in those receiving non-DCCTs.
- A DCCT in empiric therapy is a protective factor for mortality in patients with severe sepsis or septic shock.

Abbreviations

APACHE II: Acute Physiology and Chronic Health Evaluation II; DCCT: different-class combination therapy; ICU: intensive care unit.

Acknowledgements

We received statistical support from David Suarez, MSc from Unidad de Epidemiología, Fundación Parc Tauli, Universidad Autónoma de Barcelona. Barcelona, Spain; and data monitoring from Gemma Gomà, research nurse from Centro de Críticos, Hospital de Sabadell. Sabadell, Spain.

The Edusepsis Study Group included Ana Navas, Ricard Ferrer, Antonio Artigas (Hospital de Sabadell, Consorci Hospitalari Parc Tauli); María Álvarez (Hospital de Terrassa); Josep Maria Sirvent, Sara Herranz Ulldemolins (Hospital Universitari Josep Trueta de Girona); Pedro Galdós, Goiatz Balziscueta (Hospital General de Móstoles); Pilar Marco, Izaskun Azkarate (Hospital de Donostia); Rafael Sierra (Hospital Universitario Puerta del Mar); José Javier Izua (Hospital Virgen del Camino); José Castaño (Hospital Universitario Virgen de las Nieves); Alfonso Ambrós, Julian Ortega (Hospital General de Ciudad Real); Virgilio Corcoles (Complejo Hospitalario Universitario de Albacete); Luis Tamayo (Hospital Río Carrión); Demetrio Carriedo, Milagros Llorente (Hospital de León); Paz Merino, Elena Bustamante (Hospital Can Misses); Eduardo Palencia, Pablo García Olivares, Patricia Santa Teresa Zamarro (Hospital Gregorio Marañón Madrid); Carlos Pérez (Hospital Santiago Apóstol); Ana Renedo (Hospital Morales Messeguer); Silvestre Nicolás-Franco (Hospital Rafael Méndez); María Salomé Sánchez (Hospital Vega Baja); Francisco Javier Gil (Hospital Santa María del Rosell); María Jesús Gómez (Hospital General Universitario Reina Sofía de Murcia); Enriquo Piacentini (Hospital Mútua de Terrassa); Ana Loza (Hospital Universitario de Valme); Jordi Ibáñez (Hospital Son Dureta); Silvia Rodríguez (Hospital de Manresa); Jose Ángel Berezo, Jesús Blanco (Hospital Río Hortega Valladolid); Angeles Gabán, M^a Jesús López Cambra, Alec Tallet (Hospital General de Segovia); Miguel Martínez, Jose Antonio Fernández, Fernando Callejo, M^a Jesús López Pueyo (Hospital General Yagüe); Francisco Gandía (Hospital Clínico Universitario de Valladolid); M^a José Fernández (Hospital Santa Bárbara); Juan Carlos Ballesteros (Hospital Universitario de Salamanca); María Teresa Antuña, Santiago Herrero (Hospital de Cabueñes); Manuel Valledor, M^a Jose Gutierrez (Hospital San Agustín); Carmen Pérez (Hospital Universitario Insular Gran Canaria); Oscar Rodríguez (Hospital Clínico Universitario de Valencia); Rafael Dominguez (Hospital Alto Guadalquivir); Josefa Peinado (Empresa Pública Hospital de Poniente); María Victoria de la Torre, Cristina Salazar (Hospital Virgen Victoria de Málaga); M^a Cruz Martín, Joaquín Ramon (Centro Médico Delfos); Fernando Iglesias Llaça, Lorena Forcelledo Espina, Francisco Taboada Costa, José Antonio Gonzalo Guerra (Hospital Universitario Central de Asturias); Francisco José Guerrero, Felipe Cañada, M^a Milagros Balaguer, Isabel Martín, Carmen López, Daniel Sánchez (Hospital Torrecardenas); Josep Costa, Calizaya (Hospital de Barcelona SCIAS); Angel Arenaza, Ana M^a Morillo, Daniel Del Toro, Tomás Guzman (Hospital Virgen de la Macarena); Antonio Blesa, Fernando Martínez, Alejandro Moneo (Hospital San Carlos); M^a Jesús Broch (Hospital de Sagunt); Jose Antonio Camacho (Hospital San Agustín de Linares); Francisco J. García (Hospital de Montilla); Xosé Luis Pérez (Hospital Universitario de Bellvitge); Nieves García (Hospital Universitario La Princesa); Juan Carlos Ruiz, Jesús Caballero, Esther Francisco, Tania Requena, Adolfo Ruiz, José Luis Bóveda (Hospital Universitari Vall Hebrón); José Miguel Soto, Constantino Tormo (Hospital Universitario Dr Peset); Rafael Blancas (Hospital La Mancha-Centro); Manuel Quintana, Miguel Ángel Taberna (Hospital Nuestra Sra del Prado); Jose Maria Añon, Juan B. Aranjó (Hospital Virgen de la Luz); Manuel Rodríguez (Hospital Juan Ramon Jiménez); José Maria Garcia

(Hospital La Serranía de Ronda); M^a Isabel Rodríguez (Hospital General de Baza); M^a Jesús Huertos (Hospital Universitario Puerto Real); Carlos Ortiz (Hospital Virgen del Rocío); M^a Eugenia Yuste (Hospital Universitario San Cecilio); Juan Francisco Machado (Hospital Santa Ana-Motril); Dolores Ocaña (Hospital La Inmaculada); Ramón Vegas (Hospital Valle de los Pedroches); and Luis Vallejo (Hospital SAS La Linea).

Author details

¹Intensive Care Unit, Critical Care and Emergency Department, Virgen del Rocío University Hospital, Avda. Manuel Siurot s/n, Seville 41013, Spain. ²Instituto de Biomedicina de Sevilla (IBIS), Virgen del Rocío University Hospital/CSIC/Seville University, 41013 Seville, Spain. ³Spanish Network for Research in Infectious Disease (REPI), Virgen del Rocío University Hospital, Avda. Manuel Siurot, s/n. 41013, Seville, Spain. ⁴Critical Care Center, Sabadell Hospital, Autonomous University of Barcelona, Corporació Sanitaria Universitària Parc Taulí, 08208 Sabadell, Spain. ⁵Intensive Care Unit, Mútua Terrassa University Hospital, University of Barcelona, Plaça Dr, Robert 5, Terrassa, 08221, Barcelona, Spain. ⁶CIBER-Enfermedades Respiratorias. ⁷Intensive Care Unit, General Yagüe Hospital, Avda del Cid Campeador, 96 09005 Burgos, Spain. ⁸Medical Intensive Care Unit, Rhode Island Hospital/Brown University, 593 Eddy St., Providence, RI 02903, USA.

Authors' contributions

As principal investigator, ADM had full access to all data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design were performed by ADM, MLMG, RF, AA, JGM. RF completed the acquisition of data. Analysis and interpretation of data were performed by ADM and RF. Drafting of the manuscript was executed by ADM and JGM. Critical revision of the manuscript for important intellectual content was done by MLMG, COL, EP, MJLP, IML, ML, and AA. RF and AA carried out the Edusepsis General Coordination and Surviving Sepsis Campaign coordination by ML. All authors critically revised and approved the manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 30 July 2012 Revised: 9 October 2012

Accepted: 18 October 2012 Published: 18 November 2012

References

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: **Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.** *Crit Care Med* 2001, **29**:1303-1310.
2. Esteban A, Frutos-Vivar F, Ferguson ND, Penuelas O, Lorente JA, Gordo F, Honrubia T, Algora A, Bustos A, Garcia G, Diaz-Regañón IR, de Luna RR: **Sepsis incidence and outcome: contrasting the intensive care unit with the hospital ward.** *Crit Care Med* 2007, **35**:1284-1289.
3. Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, Sicignano A, Palazzo M, Moreno R, Boulme R, Lepage E, Le Gall R: **Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study.** *Intensive Care Med* 2002, **28**:108-121.
4. Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, Perez XL, Sirvent JM: **Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study.** *Am J Respir Crit Care Med* 2009, **180**:861-866.
5. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C: **Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis.** *Crit Care Med* 2003, **31**:2742-2751.
6. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL: **Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.** *Intensive Care Med* 2008, **34**:17-60.
7. Al-Hasan MN, Wilson JW, Lahr BD, Thomsen KM, Eckel-Passow JE, Vetter EA, Tleyjeh IM, Baddour LM: **Beta-lactam and fluoroquinolone combination antibiotic therapy for bacteremia caused by gram-negative bacilli.** *Antimicrob Agents Chemother* 2009, **53**:1386-1394.

8. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, Barcenilla F, Escobresca-Ortega A, Ochoa M, Cayuela A, Rello J: **Optimal management therapy for *Pseudomonas aeruginosa* ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy.** *Crit Care Med* 2007, **35**:1888-1895.
9. Weiss K, Tillotson GS: **The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia.** *Chest* 2005, **128**:940-946.
10. Kumar A, Zarychanski R, Light B, Parrillo J, Maki D, Simon D, Laporta D, Lapinsky S, Ellis P, Mirzanejad Y, Martinka G, Keenan S, Wood G, Arabi Y, Feinstein D, Kumar A, Dodek P, Kravetsky L, Doucette S: **Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis.** *Crit Care Med* 2010, **38**:1773-1785.
11. Ferrer R, Artigas A, Levy MM, Blanco J, Gonzalez-Diaz G, Garnacho-Montero J, Ibanez J, Palencia E, Quintana M, de la Torre-Prados MV: **Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain.** *JAMA* 2008, **299**:2294-2303.
12. Suarez D, Ferrer R, Artigas A, Azkarate I, Garnacho-Montero J, Goma G, Levy MM, Ruiz JC: **Cost-effectiveness of the Surviving Sepsis Campaign protocol for severe sepsis: a prospective nation-wide study in Spain.** *Intensive Care Med* 2011, **37**:444-452.
13. Knaus WA, Wagner DP, Draper EA, Zimmerman JE, Bergner M, Bastos PG, Sirio CA, Murphy DJ, Lotring T, Damiano A, Harrell FE: **The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults.** *Chest* 1991, **100**:1619-1636.
14. Angel Diaz M, Ramon Hernandez J, Martinez-Martinez L, Rodriguez-Bano J, Pascual A: **[Extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in Spanish hospitals: 2nd multicenter study (GEIH-BLEE project, 2006)].** *Enferm Infecc Microbiol Clin* 2009, **27**:503-510.
15. Kock R, Becker K, Cookson B, van Gemert-Pijnen JE, Harbarth S, Kluytmans J, Mielke M, Peters G, Skov RL, Struelens MJ, Tacconelli E, Navarro Torné A, Witte W, Friedrich AW: **Methicillin-resistant *Staphylococcus aureus* (MRSA): burden of disease and control challenges in Europe.** *Euro Surveill* 2010, **15**:19688.
16. Kumar A: **Optimizing antimicrobial therapy in sepsis and septic shock.** *Crit Care Clin* 2009, **25**:733-751, viii.
17. de With K, Meyer E, Steib-Bauert M, Schwab F, Daschner FD, Kern WV: **Antibiotic use in two cohorts of German intensive care units.** *J Hosp Infect* 2006, **64**:231-237.
18. Rodriguez A, Mendia A, Sirvent JM, Barcenilla F, de la Torre-Prados MV, Sole-Violan J, Rello J: **Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock.** *Crit Care Med* 2007, **35**:1493-1498.
19. Rotschafer JC, Ullman MA, Sullivan CJ: **Optimal use of fluoroquinolones in the intensive care unit setting.** *Crit Care Clin* 2011, **27**:95-106.
20. Dupont H, Carbon C, Carlet J: **Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial: The Severe Generalized Peritonitis Study Group.** *Antimicrob Agents Chemother* 2000, **44**:2028-2033.
21. Damas P, Garweg C, Monchi M, Nys M, Canivet JL, Ledoux D, Preiser JC: **Combination therapy versus monotherapy: a randomised pilot study on the evolution of inflammatory parameters after ventilator associated pneumonia [ISRCTN31976779].** *Crit Care* 2006, **10**:R52.
22. Heyland DK, Dodek P, Muscedere J, Day A, Cook D: **Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia.** *Crit Care Med* 2008, **36**:737-744.
23. Baddour LM, Yu VL, Klugman KP, Feldman C, Ortvist A, Rello J, Morris AJ, Luna CM, Snyderman DR, Ko WC, Chedid MB, Hui DS, Andremon A, Chiou CC: **Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia.** *Am J Respir Crit Care Med* 2004, **170**:440-444.
24. Lodise TP, Kwa A, Cosler L, Gupta R, Smith RP: **Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.** *Antimicrob Agents Chemother* 2007, **51**:3977-3982.
25. Tessmer A, Welte T, Martus P, Schnoor M, Marre R, Suttrop N: **Impact of intravenous (beta)-lactam/macrolide versus (beta)-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia.** *J Antimicrob Chemother* 2009, **63**:1025-1033.
26. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L: **Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials.** *BMJ* 2004, **328**:668.
27. Safdar N, Handelsman J, Maki DG: **Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis.** *Lancet Infect Dis* 2004, **4**:519-527.
28. Kumar A, Safdar N, Kethireddy S, Chateau D: **A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study.** *Crit Care Med* 2010, **38**:1651-1664.
29. Giamarellos-Bourboulis EJ, Pechere JC, Routsis C, Plachouras D, Kollias S, Raftogiannis M, Zervakis D, Baziaka F, Koronaios A, Antonopoulou A, Markaki V, Koutoukas P, Papadomichelakis E, Tsaganos T, Armaganidis A, Koussoulas V, Kotanidou A, Roussos C, Giamarellou H: **Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia.** *Clin Infect Dis* 2008, **46**:1157-1164.
30. Metersky ML, Ma A, Houck PM, Bratzler DW: **Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones.** *Chest* 2007, **131**:466-473.
31. Parnham MJ: **Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections.** *Curr Opin Infect Dis* 2005, **18**:125-131.
32. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D: **Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis.** *Am J Med* 2003, **115**:529-535.

doi:10.1186/cc11869

Cite this article as: Díaz-Martín et al.: Antibiotic prescription patterns in the empiric therapy of severe sepsis: combination of antimicrobials with different mechanisms of action reduces mortality. *Critical Care* 2012 **16**:R223.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

